Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Vorasidenib in Pediatric IDH-mutant Grade 2 Glioma
jRCT2031260159Phase 2Not yet recruiting
- Sponsor
- Servier
- Start
- Mar 2026
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of vorasidenib in astrocytoma and Oligodendroglioma (OG), sponsored by Servier. Primary endpoints: Adverse Events, Severity of AEs and 14 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
vorasidenib
03
Conditions
astrocytomaOligodendroglioma (OG)
Beyond the preview
Go deeper on jRCT2031260159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260159.